UK launch for Ajovy injector pen
Teva’s new device allows migraine sufferers to self-administer the drug
Read More
Tag: fremanezumab
NICE publishes final guidance backing Teva’s Ajovy for migraine
One in seven UK adults is affected by migraine
Read More
IONTAS, Teva announce new antibody optimisation agreement
Teva recently halted its Ajovy clinical development.
Read More
European approval for Teva’s migraine drug Ajovy
The drug is a pre-filled syringe for the prophylaxis of migraine in adults who have at least four migraine days per month.
Read More
Teva’s anti-CGRP drug Ajovy cleared for migraine prevention
US regulators have approved Teva’s Ajovy for the preventative treatment of migraine in adults.
Read More
Teva pulls fremanezumab cluster headaches trial
Teva is discontinuing a late-stage trial assessing the efficacy of its experimental anti-CGRP therapy fremanezumab in reducing cluster headaches.
Read More
Teva’s anti-CGRP drug under review for migraine
US regulators are now reviewing Teva Pharmaceutical’s experimental anti-CGRP therapy fremanezumab for the preventive treatment of migraine, and have also granted the drug a fast track designation for the prevention of cluster headache.
Read More
Stellar results for Novartis, Teva anti-CGRP migraine drugs
The New England Journal of Medicine has published two separate studies showing that CGRP-targeting therapies – namely Novartis’ erenumab and Teva’s fremanezumab – significantly cut the number of headache days in patients with episodic or chronic migraine, respectively.
Read More
Teva’s migraine drug hits key PhIII goal
Teva has unveiled data showing that its experimental migraine drug fremanezumab hit key efficacy targets in a late stage trial, on the back of which it expects to submit regulatory filings later this year.
Read More
- SolasCure trial shows faster healing with Aurase Wound Gel
- Gilead data show investigational HIV combination maintains viral suppression
- Verdiva Bio completes enrolment for phase 2b study of oral GLP‑1 candidate VRB‑101
- MHRA approves imlunestrant tosylate as new breast cancer treatment
- ACD440 granted orphan drug status in the EU
